Menopause
Conference Coverage
Gap in osteoporosis diagnosis and treatment stirs concern
A decline in the diagnosis and treatment of osteoporosis has experts worried about a new epidemic of fractures. Fracture liaison services and...
From the Journals
WHI hormone trials offer reassurance on long-term mortality risk
New data from the WHI trials suggest that the use of conjugated equine estrogens alone or with medroxyprogesterone acetate is safe for 5-7 years...
News from the FDA/CDC
Sleep issues vary by menopausal status
Report examines sleep duration and quality in women aged 40-59 years.
Conference Coverage
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
An analysis of a 7-year, open-label extension study of denosumab in women found a 0.05% overall rate of jaw osteonecrosis and a 0.7% rate...
Clinical Review
2017 Update on female sexual dysfunction
New and emerging treatment options hold promise for improving outcomes in this undertreated disorder
From the Journals
Focus on lifestyle to manage menopause symptoms after breast cancer
Smoking cessation, weight loss and exercise, limiting alcohol intake, maintenance of adequate vitamin D and calcium levels, and a healthy diet...
Conference Coverage
Anabolic agents for osteoporosis have limited role so far
Parathyroid hormone and parathyroid hormone-related protein analogs show promise for osteoporosis, but, for now, they’re reserved for the most...
Product Review
Product Update: Intrarosa, ZEJULA, Signia Stapling System, TYMLOS, Videssa Breast
NONESTROGEN PRODUCT FOR DYSPAREUNIAIntrarosa (prasterone 6.5 mg), from AMAG Pharmaceuticals and Endoceutics, Inc, is announced as the only FDA-...
Clinical Review
2017 Update on menopause
The North American Menopause Society has updated hormone therapy guidelines; herein, what you need to know. Plus, a continued call for the boxed...
Conference Coverage
Romosozumab cuts new vertebral fracture risk by 73%, but safety data are concerning
MADRID – Investigational bone-building drug looks promising, but safety concerns emerge.
Conference Coverage
Endometriosis after menopause: Weigh the treatment risks
VANCOUVER – Age and previous disease severity are important factors in weighing whether to prescribe hormone therapy for postmenopausal women with...